A Feasibility Study of Group Metacognitive Therapy Versus Mindfulness Meditation Therapy

Group Metacognitive Therapy Versus Mindfulness Meditation Therapy in a Transdiagnostic Patient Sample: A Feasibility Study

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02096484

Acronym

MCT

Enrollment

Registered

2014-03-26

Start date

2014-08-31

Completion date

2016-06-30

Last updated

2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Generalized Anxiety Disorder

Keywords

Metacognitive therapy, mindfulness meditation therapy, group therapy, generalized anxiety disorder, Group Based Metacognitive Therapy, Group Based Mindfulness Meditation Therapy

Brief summary

The study will examine the effectiveness of group metacognitive therapy in comparison with group meditation therapy, in patients with Generalised Anxiety Disorder. Individuals will be randomly assigned to either meditation or metacognitive therapy and undergo 8 group therapy sessions of their respective treatment condition.

Interventions

BEHAVIORALGroup Metacognitive Therapy

BEHAVIORALMindfulness Meditation Therapy

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* individual's score on the GAD-7 & PHQ-9 * individuals who meet the DSM-IV (Diagnostic and Statistical Manual) criteria for generalized anxiety disorder

Exclusion criteria

* Individuals with major depressive disorder * Individuals who report suicidality * Individuals with a brain injury or neurological insult * Individual who currently engage in substance abuse * Individuals with bipolar disorder * Individuals with psychotic symptoms * Individuals who cannot converse or read English

Design outcomes

Primary

Measure	Time frame
Hospital Anxiety and Depression Scale (HADS)	Administered at pre treatment, mid treatment, post treatment, and 6 month follow up

Secondary

Measure	Time frame
CAS-I	Administered at pre treatment, mid treatment, post treatment, and 6 month follow up
GAD-7	Completed prior to week 1 of treatment.This will be administered prior to treatment as a screening measure for levels of anxiety.
PHQ-9	Completed prior to week 1 of treatment.This will be administered prior to treatment as a screening measure for levels of depression.

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026